EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Aditi R Saxena iD, Juan P Frias, Donal N Gorman, Rene N Lopez, Nabil Andrawis, Nikolaos Tsamandouras, Morris J Birnbaum

Diabetes, Obesity and Metabolism · 2023-10 · 25 (10) · 2805-2814

DOI: 10.1111/dom.15168 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 13.06.2023. Verfasst von Aditi R Saxena und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the tolerability, safety and pharmacodynamics of different dose‐escalation schemes of the oral small‐molecule glucagon‐like peptide‐1 receptor (GLP‐1R) agonist danuglipron. Materials and Methods This Phase 2a, double‐blind, placebo‐controlled, parallel‐group study randomly assigned adults with type 2 diabetes (T2D) treated with metformin to placebo or danuglipron (low [5‐mg] or high [10‐mg] starting dose, with 1‐ or 2‐week dose‐escalation steps, to target doses of 80, 120 or 200 mg twice daily [BID]) and adults with obesity without diabetes to placebo or danuglipron 200 mg BID.

Results

Participants with T2D (n = 123, mean glycated haemoglobin [HbA1c] 8.19%) or obesity without diabetes (n = 28, mean body mass index 37.3 kg/m 2 ) were randomly assigned and treated. Discontinuation from study medication occurred in 27.3% to 72.7% of participants across danuglipron groups versus 16.7% to 18.8% for placebo, most often due to adverse events. Nausea (20.0%‐47.6% of participants across danuglipron groups vs. 12.5% for placebo) and vomiting (18.2%‐40.9% danuglipron vs. 12.5% placebo, respectively) were most commonly reported in participants with T2D. Gastrointestinal adverse events were generally related to danuglipron target dose and were not substantially affected by starting dose. In participants with T2D, least squares mean changes from baseline in HbA1c (−1.04% to −1.57% across danuglipron groups vs. −0.32% for placebo), fasting plasma glucose (−23.34 mg/dL to −53.94 mg/dL danuglipron vs. −13.09 mg/dL placebo) and body weight (−1.93 to −5.38 kg danuglipron vs. −0.42 kg placebo) at Week 12 were generally statistically significant for danuglipron compared with placebo ( P < 0.05).

Conclusions

Danuglipron resulted in statistically significant reductions in HbA1c, FPG and body weight over 12 weeks, in the setting of higher discontinuation rates and incidence of gastrointestinal adverse events with higher target doses. Clinicaltrials.gov identifier: NCT04617275.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2AdultHumansGlycated HemoglobinHypoglycemic AgentsBody WeightObesityDouble-Blind MethodTreatment OutcomeBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1 receptor agonistdanugliprontype 2 diabetes

Substanzen

Glycated HemoglobinHypoglycemic AgentsBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts, USA.
  • Velocity Clinical Research, Los Angeles, California, USA.
  • Early Clinical Development, Pfizer Worldwide Research and Development, and Medical, Cambridge, UK.
  • Early Clinical Development, Pfizer Worldwide Research and Development, and Medical, Groton, Connecticut, USA.
  • Manassas Clinical Research Center, Manassas, Virginia, USA.
  • Early Clinical Development, Pfizer Worldwide Research and Development, and Medical, Cambridge, Massachusetts, USA.

ORCID-Profile: Aditi R Saxena

Förderung

  • Pfizer

Zitieren

APA

Saxena, A. R., Frias, J. P., Gorman, D. N., Lopez, R. N., Andrawis, N., Tsamandouras, N., & Birnbaum, M. J. (2023). Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes. Diabetes, Obesity and Metabolism, 25(10), 2805-2814. https://doi.org/10.1111/dom.15168

Vancouver

Saxena AR, Frias JP, Gorman DN, Lopez RN, Andrawis N, Tsamandouras N, et al. Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes. Diabetes, Obesity and Metabolism. 2023;25(10):2805-2814. doi:10.1111/dom.15168

BibTeX
@article{Saxena2023,
  author = {Saxena, Aditi R and Frias, Juan P and Gorman, Donal N and Lopez, Rene N and Andrawis, Nabil and Tsamandouras, Nikolaos and Birnbaum, Morris J},
  title = {Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {10},
  pages = {2805--2814},
  doi = {10.1111/dom.15168}
}
Kostenlos starten →